Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italy's biopharmaceutical company, Dompé has signed a definitive agreement to acquire remaining 51% stake in Anabasis, a privately held Italian research and development biopharmaceutical company.
Subscribe to our email newsletter
In January 2011, Dompé has acquired 49% stake in Anabasis and also patent rights for the use of NGF to treat neurotrophic keratitis (NK).
Dompé will become the sole shareholder of Anabasis by acquiring remaining 51% of its share capital for an undisclosed amount.
Dompé CEO Eugenio Aringhieri said the acquisition of Anabasis will create new strategic positions for Dompé in the growing ophthalmic area.
Anabasis CEO Francesco Sinigaglia said Dompé will provide the firm with the necessary resources and expertise to demonstrate the efficacy of products through regulatory clinical development.
Anabasis is focused on the development of innovative therapies for the eye.